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Abstract  
An isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS) method 
with a fast sample preparation using homemade clean-up cartridges was developed for 
simultaneous determination of co-occurring mycotoxins exemplified with aflatoxin B1 
(AFB1) and T-2 toxin (T-2) in representative biomatrices of rat plasma, heart, liver, kidney, 
spleen, lung and brain in a total run time of 7 min. The established approach using stable 
internal standards of [
13
C17]-AFB1 and [
13
C24]-T-2 was extensively validated by determining 
the specificity, linearity (R
2≥0.9990), sensitivity (lower limit of quantitation at 0.05 ng mL-1), 
accuracy (70.9%-107.7%), precision (RSD≤14.2%) and stability (≥70.8%). Based on this 
methodological advance, the subsequent kinetics and tissue distribution after oral 
administration of 0.5 mg kg
-1
 b.w. of both AFB1 and T-2 in rats were thoroughly studied. As 
revealed, both AFB1 and T-2 were rapidly eliminated with the half-life time (t1/2) in plasma of 
8.44±4.02 h and 8.12±4.05 h, respectively. Moreover, AFB1 accumulated in all organs where 
the highest concentration was observed in liver (1.34 μg kg-1), followed by kidney (0.76 μg 
kg
-1
). Notably, only low levels of T-2 were observed in spleen (0.70 μg kg-1) and in liver (0.15 
μg kg-1). The achieved data as supporting evidence would substantially promote the practical 
application of the proposed LC-MS/MS method for in vivo toxicokinetics and toxicity studies 
of co-occurring mycotoxins imitating natural incidence in rat system.  
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Introduction 
 
Mycotoxins, as the toxic secondary metabolites produced by various mold species, can 
contaminate many agricultural commodities in the field or during storage 
1-3
. Typically, 
aflatoxin B1 (AFB1) and T-2 toxin (T-2), as frequently co-occurring mycotoxins in natural 
incidence, are produced by Aspergillus and Fusarium species, respectively 
4-6
. AFB1 is a 
highly toxic and carcinogenic compound that causes disease in livestock and humans, and has 
been classified in group І as human carcinogen 7-9. Due to its hepatotoxic and 
hepatocarcinogenic properties, the content of AFB1 in foods is strictly restricted in many 
countries 
10
. T-2 can cause both acute and chronic diseases such as vomiting, diarrhea, skin 
irritation, weight loss, feed refusal and nausea, as well as neural disturbances and abortion 
11-
13
. Even so, up to now, no regulatory levels on public have been set for T-2 worldwide. 
Practically, humans can be co-exposed to two representative mycotoxins of AFB1 and T-2. 
First, the same food can be infected or invaded by different mycotoxigenic molds resulting in 
the co-occurring AFB1 and T-2 even at high concentrations in many geographic origins under 
optimum environmental conditions 
14-16
; Second, co-occurring mycotoxins can reach humans 
through the various diets and also, through milk, meat and eggs from livestock and poultry 
animals fed with different mycotoxins contaminated feedstuffs 
17-19
. The toxic effects, 
appearing in consumers exposed to co-occurring mycotoxins, are surely in accordance to the 
possible interactions of concomitantly occurring mycotoxins, which might be antagonistic, 
additive, or synergistic on different occasions 
20
. Nevertheless, knowledge regarding to the 
influence of co-occurring AFB1 and T-2 on kinetics and distribution is still unknown to date, 
where the main technical obstacle is the scare of simple, accurate and highly sensitive means 
capable of quantifying target mycotoxin molecules from complicated biological samples. 
Therefore, development and validation of desirable analytical methods for the simultaneous 
determination of co-occurring AFB1 and T-2 in a variety of biomatrices are very valuable, 
which are also the reliable tools for the kinetic and distribution studies to reveal the 
bidirectional effects of co-occurring AFB1 and T-2 in experimental animal system, 
minimizing the use of laboratory animals and the cost of analysis, with the premise of 
accuracy and precision. 
Various methods have been employed to individually analyze single mycotoxin of either 
AFB1 or T-2 in biological fluids and tissues. These generally include radioactivity, thin-layer 
chromatography (TLC) and high performance liquid chromatography (HPLC) combined with 
different detectors 
8, 21-28
. Radioactivity is very sensitive, which can be utilized in mass 
balance and tissue distribution studies, but not suitable for kinetic analysis due to the serious 
interferences of the extensive metabolites 
29
. TLC and HPLC coupled to UV or fluorescence 
detectors (FLD) could supply acceptable sensitivity in premise of tedious derivation process 
due to the weak chromophore of analyzed mycotoxins. Since the latest decade, liquid 
chromatography tandem mass spectrometry (LC–MS/MS) plays a pivotal role in trace 
analysis of multiple mycotoxins because of its high sensitivity and selectivity 
30-32
. However, 
molecules originating from the sample matrix that co-elute with the compounds of interest 
may have significant impact on the ionization process causing ionization 
suppression/enhancement, and consequently on the accuracy of the method. Namely, the two 
main limiting features when detecting multiple mycotoxins in different biomatrices are the 
variety of the physico-chemical properties of the involved mycotoxins and the complex 
composition of sample matrix. Hitherto, although several LC-MS/MS methods have already 
been developed for simultaneous determination of AFB1 and T-2 in food and feedstuffs 
7
, no 
uniform method with sufficient simplicity, relative rapidity and high sensitivity has been 
reported, which could be applicable for different biomatrices i.e., plasma, heart, liver, spleen, 
lung, kidney and brain, with the complicated substances as interferences.  
In the present study, a simple and sensitive LC-MS/MS method based on a combination of 
isotope dilution and fast sample preparation using homemade clean-up cartridges was 
developed and then validated for simultaneous quantitation of co-occurring AFB1 and T-2 in 
rat plasma, heart, liver, spleen, lung, kidney and brain. The utmost advantage of this proposed 
analytical method is that identical conditions can be utilized for analyzing AFB1 and T-2 in 
all the above mentioned biomatrices. Furthermore, the small amount of sample needed, the 
low volume of solvents used and the fact that immunoaffinity columns (IAC) are not required 
for this assay, making it more rapid, economical and practical for analyses of AFB1 and T-2 
in such small animal experiments. This method was then successfully applied to the kinetics 
and tissue distribution studies after oral administration of co-occurring AFB1 and T-2 in rat 
system, demonstrating its potential for toxicological or toxicokinetic studies. 
 Experimental section 
 
Safety precautions 
 
AFB1 and T-2 are toxic substances, which should be manipulated in solution, avoiding the 
formation of dust and aerosols. FPP3 masks and nitrile gloves were used when all related 
procedures were carried out. 
 
Chemicals and reagents  
 
The standards of AFB1 (molecular weight (MW), 312), T-2 (MW, 467) and their internal 
standards (ISs) [
13
C17]-AFB1 (MW, 329), [
13
C24]-T-2 (MW, 491) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). The chemical structures of AFB1 and T-2 are shown in 
Fig. S-1 (Supplementary data). Acetonitrile and methanol, purchased from Merck (Darmstadt, 
Germany), were both HPLC grade. Milli-Q quality water (Millipore, Billerica, MA, USA) 
was used throughout the whole analysis. All other reagents were of analytical grade.  
Silica gel (Product No. 236799), active carbon (Product No. C3345), alumina neutral (Product 
No. 199974), alumina base (Product No. 199443), florisil (Product No. 220736) and 
kieselguhr (Product No. D3877) were all purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Polypropylene SPE empty tubes (3 mL) and frits were from Shenzhen Biocomma 
Biotech CO, LTD (Shenzhen, China). High quality poly (9, 9-diethylfluorene) (PDEF) 
syringe filters (0.22 µm pore size, 13 mm diameter) were supplied by Millipore. 
 
Apparatus 
 
LC-MS/MS (TSQ QUANTUM ULTRA, Thermo Scientific, Brookfield, USA) using selected 
reaction monitoring (SRM) mode was used for AFB1 and T-2 analyses in different 
biomatrices. Separation was performed on a Thermo Hypersil Gold column (100 mm×2.1 
mm, 3.0 µm) at 35
 ◦
C, with a mobile phase flow rate of 0.35 mL min
-1
. Water (containing 0.25 
mmol L
−1
 ammonium acetate and 0.05% formic acid) (A) and methanol (containing 0.25 
mmol L
−1
 ammonium acetate and 0.05% formic acid) (B) were used as the mobile phase. A 
linear gradient elution program was applied as follows: initial 30% B, 3 min 100% B, 3.8 min 
100% B, 4 min 30% B, and hold on for a further 3 min for re-equilibration, giving a total run 
time of 7 min. The injection volume was 5.0 μL (full loop). The mass spectrometer was 
operated with an electrospray source in positive ionization mode (ESI
+
). The following 
settings were used for MS/MS conditions: spray voltage, 4 kV; vaporizer temperature, 300 
◦
C; 
sheath gas pressure, 30 psi; aux valve flow, 30 arb; capillary temperature, 350 
◦
C. Data were 
acquired and processed by Xcalibur software (Thermo Scientific, Brookfield, USA). 
 
Standard solutions 
 
Accurately weighed solid portions (1.0 mg) of AFB1 and T-2 were dissolved in 2 mL of pure 
ethanol, and the solution was diluted with water to prepare a mixture of AFB1 and T-2 at a 
concentration of 0.1 mg mL
-1
 in 20% of ethanol aqueous solution, which was used for the oral 
administration of rats.  
For LC-MS/MS analysis, solid portions of AFB1 and T-2 were individually dissolved in 
acetonitrile to prepare 0.1 mg mL
-1 
of stock solution, and stored at -20 
◦
C under darkness. The 
stock solution was diluted step by step with the mixture of acetonitrile and water containing 
10 mmol L
-1
 ammonium acetate (20/80, v/v) to prepare work solution. The stock solutions of 
the two ISs ([
13
C17]-AFB1 and [
13
C24]-T-2) were directly used the purchased product and 
diluted with the same mixed solution to 50 ng mL
−1
. All work solutions were prepared 
immediately before use. 
 
Animals 
 
Male Sprague–Dawley (SD) rats, weighing 200±20 g, were purchased from Fudan University 
Laboratory Animal Center (Shanghai, China). The study was approved by the Animal Ethics 
Committee of Shanghai Academy of Agricultural Sciences. 
On the day of arrival, the animals were randomly distributed to polycarbonate cages with 
stainless steel covers for one week to allow acclimatization to the environmental conditions: 
12 h day/night cycle, temperature 25±2 
◦
C, standard diet and water. 
For the kinetics studies in plasma, six rats were administrated one single dose of 0.5 mg/kg 
b.w. AFB1 and T-2 by gavage with the volume of about 1 mL of ethanol aqueous solution of 
pure ethanol in water (20/80, v/v, 0.1 mg mL
-1
) depending on the weight of the rat itself. 
Blood samples (300 µL) were collected via the caudal vein catheter prior to dosage (0 min) 
and at 0.083, 0.167, 0.5, 1.0, 1.5, 2.0, 2.5, 5, 7.5, 10.0, 12.0 and 24.0 h thereafter with minor 
modifications according to the previous protocols 
33
. The blood samples were immediately 
transferred to heparinized tubes and centrifuged at 4000 g for 5 min. All plasma samples were 
pipetted and stored at -20 °C until analysis. 
For the tissue distribution studies, fifty four rats were randomly divided into nine groups (n = 
6) and administrated an oral dose of 0.5 mg/kg b.w. AFB1 and T-2 by gavage. After 
euthanizing by cervical dislocation prior to dosage (0 h) and at 0.5 h, 1 h, 2 h, 4 h, 12 h 24 h, 
48 h and 72 h thereafter, the tissues of heart, liver, spleen, lung, kidney and brain were 
excised and blot dried. In order to minimize the differences generated from various cell types 
in the organs and take a representative sample, the whole tissues were individually 
homogenized with normal saline (m/v, 1/3), and the homogenates were stored at −20 ◦C until 
analysis. 
For investigation of tissue accumulation, six rats received a daily administration of 0.25 
mg/kg b.w. AFB1 and T-2 by oral gavages during 20 days, while another six rats were 
administrated with normal saline as control. The animals were euthanized 24 h after the last 
administration, and the tissues were dealt as described above. 
 
Preparation of homemade clean-up cartridges 
 
Silica gel (0.09 g) was accurately weighed into a 3 mL hollow SPE cartridge and was shaken 
to compact the silica gel. Then, 0.01 g of florisil was added. After shaking, florisil was then 
covered by a frit at the end to ensure the upper surface smooth and flat. 
 
Sample pretreatment 
 
To the plasma/tissue homogenates (100 μL), 10 μL of IS solution (50 ng mL−1) was added, 
followed by the addition of 700 μL of acetone for participation of proteins. The mixture was 
vortex-mixed for 1 min and transferred into SPE cartridges. The cartridges were eluted with 3 
mL of methanol. The collected eluent was evaporated to dryness by a gentle stream of 
nitrogen gas at 40 
◦
C. The residue was reconstituted in 100 μL mixture of acetonitrile and 
water containing 10 mmol L
-1
 ammonium acetate (20/80, v/v), passed through the PDEF 
syringe filters and was ready for injection. Samples with concentrations out of the linear range 
were appropriately diluted with blank plasma/tissue homogenates and 100 μL of the dilution 
was selected and processed as described above. 
 
Method validation 
 
The method was thoroughly validated on a serial of characteristics of specificity, linearity, 
sensitivity, extraction recovery, accuracy and precision. Matrix effects as well as the stability 
of AFB1 and T-2 in plasma and tissue homogenates were also determined. 
Specificity was demonstrated by comparing chromatograms of blank plasma/tissue 
homogenates, plasma/tissue homogenates spiked with AFB1 and T-2, and plasma/tissue 
homogenates collected after the oral administration.  
Calibration curves of seven data points were plotted in the range of 0.05–100 ng mL-1 in 
solvent, plasma, heart, liver, spleen, lung, kidney and brain, respectively, and 5 ng mL
-1 
of 
each IS was included in each solvent. The sensitivity was evaluated by determining the lower 
limit of detection (LLOD) and lower limit of quantitation (LLOQ). The LLOD and LLOQ 
were defined as the concentrations of AFB1 and T-2 that yielded a signal-to-noise (S/N) ≥3 
and ≥10, which were both determined by decreasing the spike concentrations in various 
biomatrices, respectively. 
Extraction recovery was assessed using a generic SPE extraction procedure with four spiked 
levels (0.05, 1, 10, 100 ng mL
-1
). Recovery data were determined by comparing the peak 
areas (n = 6, each concentration) of AFB1 and T-2 obtained from plasma/ tissue homogenates 
spiked before extraction with that from plasma/ tissue homogenates spiked after extraction. 
Matrix effects were assessed by comparing the slope of the standard addition plot with the 
slope of the standard calibration plot with a concentration range of 0.05–100 ng mL-1 30. 
Accuracy was evaluated in the blank plasma and tissue homogenates employing the method 
of standard addition. The homogenized samples were spiked with LLOQ, low, intermediate 
and high levels of AFB1 and T-2 (0.05, 1, 10, 100 ng mL
-1
) in sextuplicate. The spiked 
samples were pretreated and analyzed by the established LC-MS/MS method. Accuracy was 
expressed as the percentage of mean calculated concentrations vs actual concentrations. 
Precision was evaluated by determining the same spiked samples in one day (intra-day 
precision) and the samples spiked with the same concentrations in four consecutive days 
(inter-day precision).  
The stability of AFB1 and T-2 in plasma and tissue homogenates was investigated by 
analyzing extracted samples at two spiked levels of 1 and 10 ng mL
-1 
stored at room 
temperature (RT) for 8 h, at –20°C for two weeks and three successive freeze–thaw cycles. 
Stability was assessed by comparing the mean concentrations of AFB1 and T-2 in the stored 
samples with those of the freshly prepared ones.  
 
Data analysis 
 
All kinetic parameters were processed by Drug and statistics (DAS) software, version 2.0 
(Shanghai, China). The parameters including peak concentration (Cmax), half-life time (t1/2), 
time of maximum plasma concentration (Tmax), area under the curve (AUC0–t), area under 
the curve from zero to infinity (AUC0–∞), total body clearance (CLz/F), mean residence time 
(MRT0–t) and mean residence time from zero to infinity (MRT0–∞) were calculated. Data for 
all response variables were reported as mean ± SD. A significance level (α) of 0.05 was 
selected. 
 
Results and discussion 
 
Optimization of the LC-MS/MS conditions 
 
The MS/MS conditions were firstly optimized for AFB1 or T-2 by individual injection of 
each standard solution (500 ng mL
-1
). Identification of precursor ions was performed in the 
full scan mode by recording m/z from 100 to 800 in both ESI
+
 and ESI
-
 mode. The results 
showed that the responses of [M+H]
+
 ions generated from AFB1 and [
13
C17]-AFB1 under 
ESI
+
 mode were obviously higher than their [M-H]
- 
ions generated under ESI
-
 mode. Then, 
313.2 (m/z) and 330.2 (m/z) were selected as the precursor ions for AFB1 and [
13
C17]-AFB1, 
respectively. For T-2 and [
13
C24]-T-2, the responses of the [M+Na]
+
 ions generated under 
ESI
+
 mode were significantly higher than those of the other ions, i.e., [M+H]
+
, [M+NH4]
+
 and 
[M-H]
-
, generated under ESI
+
 or ESI
-
 mode. As a consequence, 489.7 (m/z) and 513.7 (m/z) 
were selected as the precursors for T-2 and [
13
C24]-T-2, respectively. Based on the 
confirmation of precursor ions, two product ions for each precursor ion were selected 
according to the optimal selectivity and highest sensitivity for the target compounds. Collision 
energies were selected according to the responses of the product ions. The MS/MS 
spectrometry of AFB1 and T-2 are shown in Fig. S-1 (Supplementary data). The final 
selection of precursor ions, product ions and collision energies is shown in Table 1. 
A mixture of methanol and water was used as the mobile phase for separation of AFB1 and T-
2. After optimization, a satisfactory separation for AFB1 and T-2 was generated by linear 
gradient elution. In order to achieve high sensitivity of analysis, the ionization efficiency was 
investigated by further optimization of the composition of the mobile phase. Since ESI
+
 was 
employed in the present study, the acidic conditions would be beneficial to the ionization of 
the analytes. Therefore, water containing 0.05% formic acid, water containing 10 mmol L
−1
 
ammonium acetate, water containing 10 mmol L
−1
 ammonium formate, and water containing 
0.25 mmol L
−1
 ammonium acetate and 0.05% formic acid were compared. Results of multiple 
injections indicated that the responses of AFB1 and T-2 were substantially improved and 
higher sensitivity was subsequently obtained when 0.05% formic acid and 0.25 mmol L
−1
 
ammonium acetate were added compared to other additives. Under such situation, nice peak 
shapes and satisfactory separation efficiency were also achieved. 
 
Development of the homemade clean-up cartridges 
 
In general, matrix effects were directly related to an insufficient sample clean-up and might be 
reduced by simply injecting smaller volumes or diluting the sample, which seriously influence 
the sensitivity of the method, and were therefore inappropriate in the present study. In 
literature, IAC columns, Multisep multifunctional cartridges and Mycosep multifunctional 
cartridges are frequently used for mycotoxin purification 
31, 32, 34
. However, no commercially 
available cartridges were reported with acceptable capability for simultaneous determination 
of AFB1 and T-2 in plasma and different tissue homogenates. 
In the present study, six commercially available normal-phase materials, which were 
commonly used for the purification of the analytes in the previous studies, i.e., silica gel, 
active carbon, alumina neutral, alumina base, florisil and kieselguhr, were tested for their 
purification efficiencies. First, the recovery performance of all candidates was evaluated by 
purifying mixed standard solutions (1.5 ng mL
-1
) with the cartridges filled with one single 
material (0.1 g). The mixed solutions (100 μL) were passed through the cartridges and eluted 
with 3 mL of methanol. The eluent was collected and dried by nitrogen gas at 40 
◦
C. The 
residues were re-dissolved in 100 μL of mixed solution of acetonitrile and water containing 
10 mmol L
-1
 ammonium acetate (20/80, v/v). As indicated in Fig. 1, silica gel and florisil 
showed satisfactory recoveries (>80%). An orthogonal design L9 (3
4
) was conducted to 
optimize the ratio of silica gel to florisil, quantity of total materials and quantity of the elution 
solvent. The factors and levels were designed as shown in Table S-1 (Supplementary data). 
The mixed solution was purified by the homemade clean-up cartridges prepared according to 
the orthogonal table. The combinations of levels and factors were optimized by screening of 
nine treatments and each treatment was done in triplicate. Statistical analysis was performed 
using Student’s t-test and one-way analysis of variance. Multiple comparisons of means were 
separated at P<0.05 by the least significance difference (LSD, a=0.05) test. All computations 
were made by employing the statistical software (SAS, version 8.2). As shown in Online 
Resource 2, all of the three factors had significant effects on AFB1 and T-2 purification since 
the F values were all greater than the critical F value (19, P=0.05). The total content of AFB1 
and T-2 was highest when the ratio of silica gel to florisil was selected as 9/1, quantity of total 
materials was 0.1 g and quantity of the elution solvent was 3 mL. Consequently, a simple 
sample purification approach based on the homemade clean-up cartridges was developed. 
Afterwards, spiked plasma and different tissue homogenates were further tested. It could be 
obviously seen from the results that the sensitivities were significantly improved for AFB1 
and T-2 when the spiked extracts were purified with homemade mixed cartridges. On the 
other hand, some impurities, i.e., pigment and protein, which could reduce the lifetime of the 
analytical columns, were eliminated by the SPE cartridges. Satisfactory purification 
efficiencies evaluated by determining the matrix effects and the presence of interference 
peaks, and high recoveries were generated, supporting the strong ability of the homemade 
clean-up cartridges for the purification of co-occurring AFB1 and T-2 in different 
biomatrices. 
 
Method validation 
 
The method was selective for plasma and six different tissue homogenates since no 
interference peaks appeared at the retention time of AFB1 or T-2 in blank samples, also 
indicating that no AFB1 or T-2 existed in the regular rat feed. Chromatograms of blank 
plasma (a) and liver (d), blank plasma (b) and liver (e) spiked with AFB1 and T-2 (50 ng mL
-
1
), and rat plasma (c) and liver samples (f) at 0.5 h after oral administration of AFB1 and T-2 
in rat are shown in Fig. 2.  
The calibration curves for liquid solvent and all biomatrices constructed by isotope dilution 
method showed good linearity (R
2
 > 0.9990) over the concentration range of 0.05-100 ng mL
-
1
 (Table 2). For both mycotoxins in plasma and tissue homogenates, the LLOD and LLOQ 
were 0.01 and 0.05 ng mL
-1
, respectively (Table 2), which were desirable and obviously lower 
than those obtained in bibliography via UHPLC-FLD approaches 
35
.  
The observed matrix effects without ISs correction ranged from 73.0 to 105.8% for AFB1 and 
from 74.9 to 88.6% for T-2, suggesting that matrix effects in quantitative analysis could not 
be ignored. In order to establish an accurate method suitable for determination of co-occurring 
AFB1 and T-2 in different matrices, ISs were needed to correct the recovery losses during the 
ionization process. [
13
C17]-AFB1 and [
13
C24]-T-2 were selected, and the matrix effects were 
then calculated. The results showed that the extents of signal suppression/enhancement (SSE) 
were in the range of 90.2-108.9% for AFB1 and 90.9-100.0% for T-2, respectively, 
demonstrating that signal suppression/enhancement could be eliminated by the two ISs (Table 
3).  
The extraction recoveries of AFB1 and T-2 at LLOQ, low, intermediate and high 
concentrations (0.05, 1, 10 and 100 ng mL
-1
) were in the range of 51.6-111.3% for AFB1 and 
68.9-103.8% for T-2, respectively (Table 4). In order to minimize the losses of AFB1 and T-2 
during the extraction process on some occasions, the isotope ISs were utilized in the present 
work. As a consequence, desirable accuracy of the method ranged from 70.9 % to 107.7% for 
AFB1 and from 72.4% to 108.3% for T-2  was obtained (Table 4). Values for the precision 
were no more than 12.3% (intra-day) and 13.4% (inter-day) for AFB1, and 11.6% (intra-day) 
and 14.2% (inter-day) for T-2, respectively (Table 5). 
The stability of AFB1 and T-2 in rat plasma and tissue homogenates was fully evaluated. As 
summarized in Table 6, the results of short-term, freeze–thaw and long-term stabilities 
showed that all the samples were stable under these conditions, indicating there were no 
stability-related problems during the routine and large-scale analysis of bulk samples. 
Comparatively, this proposed simple uniform LC-MS/MS method for simultaneous 
determination of AFB1 and T-2 in different biomatrices showed higher sensitivity and faster 
sample preparation, as well as more accuracy aided by isotope ISs than the previously 
reported methods. 
 
In vivo kinetics and distribution studies 
 
The oral dose for administration was ascertained based on the data from some pilot 
experiments and previous literatures 
29, 36
, and was obviously lower than the reported median 
lethal dose (LD50) of AFB1 (5.5-17.9 mg/kg b.w. by oral) or T-2 (0.9 mg/kg b.w. by 
intravenous) in rat. The developed LC-MS/MS method was employed for kinetics 
investigation of co-occurring AFB1 and T-2 in rat plasma after oral administration at a dose 
of 0.5 mg/kg b.w. The concentration–time profiles are presented in Fig. 3. The calculated 
kinetic parameters expressed as mean ± SD are shown in Table 7. After oral administration, 
the highest concentration of AFB1 (Cmax= 16.58±1.05 ng mL
-1
) was observed with Tmax 
being 0.17 min. In previous studies, the obtained time-to-peak for AFB1 in rat was in the 
range of 2-3 h 
37, 38
. These existed differences might be due to two possibilities. First, different 
analytical techniques were utilized. The total radioactivity employed in the previous studies 
might misidentify the target analytes with the metabolites and other impurities 
29
, while LC-
MS/MS with high selectivity was developed in the present study and could eliminate the false 
positive results; second, the co-occurring AFB1 and T-2 might accelerate the distribution of 
AFB1 showing the additive toxic effects 
20
. The concentrations of T-2 in rat plasma were 
lower than that of AFB1, with a Cmax of only 0.53±0.08 ng mL
-1
. As previously reported, 
only about 2% of the dose appeared in the effluent during the metabolism experiment of 
tritiated T-2 toxin (2.3 and 230 pg) in vascularly autoperfused jejunal loops of rats 
29
. 
Similarly, it could be concluded in this study that T-2 toxin was susceptible to liver and 
intestinal first-pass effects, so that its absolute bioavailability might be negligible following 
oral administration.   
The concentration–time profiles in different tissues analyzed at 0-72 h after oral 
administration are shown in Fig. 4. The results indicated that AFB1 underwent a rapid 
distribution in the tissues. Within 1 h after administration, highest concentrations of AFB1 
were reached in all of the target tissues. Then, AFB1 was rapidly eliminated and disappeared 
within 24 h. Interestingly, AFB1 was also detected in brain homogenate, demonstrating that 
AFB1 could efficiently cross the blood–brain barrier. For T-2, very low concentrations were 
observed in heart, liver, spleen, lung, kidney, and disappeared within 4 h in all tissues, also 
indicating its low absolute bioavailability. As to tissue accumulation of AFB1 and T-2 (Fig. 
5), the highest concentration of AFB1 was observed in liver (1.34±0.02 μg kg-1), followed by 
kidney (0.76±0.03 μg kg-1), which might be related to its intensively hepatotoxic and 
carcinogenic effects. AFB1 was also detected in heart, brain, spleen and lung, indicating that 
AFB1 could also accumulate in these tissues. Comparatively, only very low concentrations of 
T-2 were observed in spleen (0.70±0.06 μg kg-1), possibly causing immunosuppressive 
activity, and then in liver (0.15±0.02 μg kg-1), suggesting that the accumulation effect of T-2 
is weak and spleen is the main accumulation organ of T-2. More importantly, the results 
demonstrated in the kinetic studies in plasma, as well as tissue distribution and tissue 
accumulation of both toxins could provide valuable references for revealing the real 
mechanism of the toxicity on humans. In further investigations, the well known metabolites 
such as the AFB1 epoxide formed in the liver and HT-2 formed from T-2, or even unknown 
metabolites in aqueous media will be studied to more clearly elucidate the metabolism of co-
occurring AFB1 and T-2.  
 Conclusions 
   
 A LC-MS/MS approach was specifically developed for simultaneous determination of co-
occurring mycotoxins exemplified with AFB1 and T-2 in plasma and different tissues of 
heart, liver, spleen, lung, kidney and brain. The homemade clean-up cartridges and isotope 
ISs as combinatorial means were utilized together to eliminate the matrix effects, thus 
ensuring the accuracy and precision of the method. Full validation indicated that the well-
established method with a total running of 7 min for each sample was highly sensitive, 
selective, fast, economic and proved to be applicable for multi-component analysis in 
different biomatrices in presence of interferences. These methodological advances guarantee 
the successful application for the kinetics study in plasma, and investigations on tissue 
distribution and accumulation after oral administration with two co-occurring mycotoxins in 
rat system. The kinetics parameter values, tissue distribution and accumulation data obtained 
in the present study might be helpful to predict the toxicokinetics and toxicity of co-occurring 
AFB1 and T-2 in animals and humans. In addition, the analytical method proposed in this 
work will benefit the subsequent in vivo evaluation on interaction of co-occurring mycotoxins, 
and provide the direct evidences imitating the natural incidence of co-occurring mycotoxin 
contaminants in cereal crops and foods through various dietary exposures.  
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Figure Captions 
 
Fig. 1 Comparison of the recovery performance of all candidate adsorbent materials by 
purifying mixed standard solutions (1.5 ng mL
-1
) with the SPE cartridges filled with one kind 
of material 
 
Fig. 2 SRM chromatograms of blank plasma (a) and liver (d), blank plasma (b) and liver (e) 
spiked with AFB1 and T-2 (50 ng mL
-1
), respectively, and rat plasma (c) and liver samples (f) 
at 0.5 h after oral administration of AFB1 and T-2 in rat 
 
Fig. 3 Mean plasma concentration–time curves of AFB1 (a) and T-2 (b) following the oral 
administration of co-occurring AFB1 and T-2 (0.5 mg/kg b.w.) in rat (n=6) 
 
Fig. 4 The concentration–time profile of AFB1 (a) and T-2 (b) after oral administration of 
AFB1 and T-2 (0.5 mg/kg b.w.) in different tissues of rat (n=6) 
 
Fig. 5 The tissue accumulation of co-occurring AFB1 and T-2 after 20 days of AFB1 and T-2 
(0.25 mg/kg b.w.) administration by oral gavage in rat (n=6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Precursor ions, product ions and collision energies for the analytes. 
Names 
Precursor 
ion(m/z) 
Primary 
product 
ion(m/z) 
Collision 
energy(eV) 
Secondary 
product 
ion(m/z) 
Collision 
energy(eV) 
AFB1 313.2 (+H
+
) 285.1 24 241.2 32 
[
13
C17]-AFB1 330.2 (+H
+
) 301.0 20 251.9 30 
T-2 489.7 (+Na
+
) 387.3 23 245.2 26 
[
13
C24]- T-2 513.7 (+Na
+
) 406.4 22 344.3 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Calibration curves of AFB1 and T-2 in liquid solvent and seven different matrices. 
Mycotoxin Matrices Slope Intercept R
2
 
Range 
(ng mL
-1
) 
Sensitivity 
(ng mL
-1
/ng g
-1a
) 
LLOD LLOQ 
AFB1 
Solvent 1.12 0.36 0.9997 0.05-100 0.01 0.05 
Plasma 1.14 0.07 0.9991 0.05-100 0.01 0.05 
Heart 1.20 0.09 0.9999 0.05-100 0.01 0.05 
Liver 1.21 0.40 0.9999 0.05-100 0.01 0.05 
Spleen 1.10 0.27 0.9997 0.05-100 0.01 0.05 
Lung 1.22 0.14 0.9995 0.05-100 0.01 0.05 
Kidney 1.21 1.44 0.9990 0.05-100 0.01 0.05 
Brain 1.01 0.89 0.9993 0.05-100 0.01 0.05 
        
T-2 toxin 
Solvent 0.022 0.009 0.9999 0.05-500 0.01 0.05 
Plasma 0.022 0.034 0.9990 0.05-500 0.01 0.05 
Heart 0.020 0.007 0.9999 0.05-500 0.01 0.05 
Liver 0.022 0.002 0.9998 0.05-500 0.01 0.05 
Spleen 0.020 0.012 0.9998 0.05-500 0.01 0.05 
Lung 0.021 0.009 0.9996 0.05-500 0.01 0.05 
Kidney 0.020 0.004 0.9998 0.05-500 0.01 0.05 
Brain 0.020 0.032 0.9993 0.05-500 0.01 0.05 
 
a
 ng mL
-1
 and ng g
-1
 refer to the LLOQ and LLOD values of AFB1 and T-2 in plasma and tissues, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 The extents of signal suppression/enhancements (SSEs) calculated using the isotope 
ISs or not (%, n=3). 
Matrices 
With ISs Without ISs 
AFB1 T-2 AFB1 T-2 
Plasma 101.8±5.1 100.0±4.5 85.1±3.2 87.8±3.4 
Heart 107.1±6.7 90.9±3.6 73.0±4.1 75.1±7.2 
Liver 108.0±2.4 100.0±7.8 100.9±10.1 88.6±5.6 
Spleen 98.2±4.3 90.9±4.3 105.8±3.2 80.9±6.4 
Lung 108.9±3.2 95.5±5.6 99.4±2.9 82.7±2.9 
Kidney 108.0±5.6 90.9±6.7 85.2±3.5 81.5±7.1 
brain 90.2±6.8 90.9±8.4 94.4±6.1 74.9±4.6 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4 Recovery tests in different matrices (n=6). 
Matrices Spiked level 
AFB1 T-2 
Accuracy 
(Mean %) 
Extraction recovery 
(Mean %) 
Accuracy 
(Mean %) 
Extraction recovery 
(Mean %) 
Plasma 
High level
 a
 102.3±7.3 56.2±3.4 95.2±4.1 71.7±3.4 
Intermediate level
 b
 107.1±5.1 56.9±4.3 95.6±3.3 69.3±3.2 
Low level
 c
 97.5±3.1 59.1±5.1 94.3±4.0 74.1±4.5 
LLOQ
d
 101.3±6.5 64.9±3.1 96.4±8.3 78.0±3.1 
Heart 
High level 98.2±4.2 79.3±4.8 84.6±4.6 77.5±2.9 
Intermediate level 95.5±6.2 69.2±3.2 83.7±1.9 70.3±5.6 
Low level 82.5±2.0 80.1±3.9 84.1±3.9 68.9±6.7 
LLOQ 90.7±11.2 82.1±5.6 88.7±7.0 73.4±3.6 
Liver 
High level 84.7±3.3 60.0±4.8 89.3±6.3 88.9±3.8 
Intermediate level 93.0±2.0 55.7±4.4 92.5±6.0 83.7±3.4 
Low level 101.9±6.6 59.9±4.1 90.8±6.5 96.8±5.6 
LLOQ 97.1±7.1 56.0±3.9 89.8±8.0 92.2±6.7 
Spleen 
High level 90.1±2.7 60.7±5.7 85.8±6.3 82.0±6.9 
Intermediate level 102.9±2.2 57.4±3.1 91.3±5.1 82.4±4.5 
Low level 100.1±4.1 57.0±1.9 96.8±8.4 93.0±4.8 
LLOQ 93.9±4.3 51.6±2.8 90.3±7.6 80.5±7.4 
Lung 
High level 91.3±6.4 54.4±3.2 92.0±2.9 84.2±6.1 
Intermediate level 98.7±4.7 52.5±3.3 108.3±7.8 91.9±5.5 
Low level 98.6±6.8 55.5±4.9 92.2±8.2 90.3±5.2 
LLOQ 100.9±5.0 54.8±2.0 84.2±3.9 84.9±5.4 
Kidney 
High level 95.9±2.0 61.2±1.1 101.8±8.8 86.7±5.5 
Intermediate level 107.7±7.0 64.1±2.3 83.3±6.2 80.4±6.7 
Low level 94.2±8.2 58.8±4.5 103.8±9.8 98.3±3.4 
LLOQ 86.5±8.8 55.0±3.2 98.2±11.6 98.0±4.3 
Brain 
High level 76.4±3.2 95.2±3.3 72.4±1.9 89.9±2.3 
Intermediate level 70.9±3.6 103.8±4.8 86.7±2.1 98.6±3.4 
Low level 89.9±5.8 111.3±5.4 85.9±3.2 103.8±5.7 
LLOQ 84.9±6.2 108.9±7.8 83.6±5.6 103.7±6.1 
a High level was designed as 100.0 ng mL-1 ;  
b Intermediate level was designed as 10.0 ng mL-1; 
c Low level was designed as 1.0 ng mL-1; 
d LLOQ was designed as 0.05 ng mL-1. 
 
 
 
 
 
 
 
 
Table 5 The intra- and inter-day precision tests of AFB1 and T-2 in different matrices (n = 6). 
Matrices Spiked level 
AFB1 T-2 
Inter-day 
(RSD %) 
Intra-day 
(RSD %) 
Inter-day 
(RSD %) 
Intra-day 
(RSD %) 
Plasma 
High level
 a
 6.6 7.1 2.8 4.3 
Intermediate level 
b
 3.0 4.8 3.9 3.5 
Low level 
c
 7.2 3.2 6.5 4.2 
LLOQ
 d
 8.4 6.4 10.2 8.6 
Heart 
High level 8.1 4.3 6.8 5.4 
Intermediate level 7.3 6.5 8.1 2.3 
Low level 5.1 2.4 7.9 4.6 
LLOQ 6.2 12.3 11.9 7.9 
Liver 
High level 3.2 3.9 2.1 7.1 
Intermediate level 4.9 2.1 7.3 6.5 
Low level 2.3 6.5 6.5 7.2 
LLOQ 5.6 7.3 8.6 8.9 
Spleen 
High level 2.1 3.0 3.1 7.3 
Intermediate level 6.5 2.1 8.7 5.6 
Low level 7.4 4.1 11.6 8.7 
LLOQ 8.6 4.6 14.2 8.4 
Lung 
High level 2.9 7.0 4.6 3.2 
Intermediate level 3.6 4.8 5.6 7.2 
Low level 4.5 6.9 7.2 8.9 
LLOQ 8.2 5.0 7.9 4.6 
Kidney 
High level 8.6 2.1 7.2 8.6 
Intermediate level 13.4 6.5 8.7 7.5 
Low level 10.9 8.7 9.1 9.4 
LLOQ 11.4 10.2 13.9 11.6 
Brain 
High level 4.3 4.2 4.9 1.9 
Intermediate level 6.5 5.1 2.3 2.1 
Low level 7.2 6.4 6.5 3.2 
LLOQ 10.1 7.3 7.8 5.6 
a High level was designed as 100.0 ng mL-1; 
b Intermediate level was designed as 10.0 ng mL-1; 
c Low level was designed as 1.0 ng mL-1;  
d LLOQ was designed as 0.05 ng mL-1. 
 
 
 
 
 
 
 
 
Table 6 Stability of AFB1 and T-2 (n = 6). 
Toxins Matrices 
Concentration 
(ng mL
-1
) 
Concentration of stored sample / Concentration of freshly prepared sample 
 (mean ± SD %) 
Short-term 
stability  
(at RT for 8h) 
Freeze–thaw 
stability 
Long-term stability 
(at -20 ℃ for 2 weeks) 
AFB1 
Plasma 
1 93.2±3.1 90.1±2.4 84.9±3.4 
100 91.2±4.1 96.8±3.2 76.5±3.8 
Heart 
1 95.1±3.6 78.8±3.4 86.6±5.2 
100 94.2±3.2 83.0±2.4 80.6±4.1 
Liver 
1 95.2±4.5 70.8±4.6 87.9±6.4 
100 91.9±2.1 88.9±6.4 92.5±5.9 
Spleen 
1 93.1±5.6 78.2±2.5 89.5±4.1 
100 91.6±3.4 79.3±3.4 80.3±3.1 
Lung 
1 92.5±2.4 85.0±5.9 84.4±3.2 
100 95.6±3.8 83.0±4.5 82.2±6.7 
Kidney 
1 97.5±4.6 74.3±6.5 80.7±5.1 
100 82.1±4.4 77.6±6.4 79.8±5.7 
Brain 
1 92.8±3.3 79.8±5.6 80.8±6.4 
100 95.5±1.9 83.1±6.2 75.2±4.1 
T-2 
Plasma 
1 82.2±10.6 91.5±2.9 83.8±2.9 
100 83.7±2.9 94.4±3.4 83.6±3.6 
Heart 
1 82.4±8.2 92.5±3.4 90.1±3.6 
100 86.0±4.9 95.6±4.2 92.8±4.1 
Liver 
1 84.7±7.1 96.5±3.4 84.1±2.9 
100 83.5±5.2 94.6±4.7 88.0±3.1 
Spleen 
1 94.8±7.2 84.9±3.2 80.8±3.7 
100 85.3±6.7 82.6±2.7 84.9±5.1 
Lung 
1 83.5±3.1 86.1±4.3 79.3±5.6 
100 95.4±4.9 83.1±2.9 84.4±3.2 
Kidney 
1 88.7±4.6 79.9±4.6 78.9±6.4 
100 86.7±5.8 82.1±3.4 81.3±6.2 
Brain 
1 82.4±4.2 81.6±4.5 77.2±7.2 
100 81.1±2.9 84.7±6.2 76.6±3.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7 Pharmacokinetic parameters of AFB1 and T-2 (0.5 mg/kg b.w.) after oral 
administration in rat (n = 6). 
Pharmacokinetic parameters Unit AFB1 T-2 
AUC(0-t) μg /L*h 36.24±0.69 0.60±0.03 
AUC(0-∞) μg /L*h 40.84±3.65 0.98±0.24 
MRT(0-t) h 5.24±0.37 3.43±0.14 
MRT(0-∞) h 8.93±3.33 10.75±5.52 
t1/2 h 8.44±4.02 8.12±4.05 
Tmax h 0.17±0.00 0.17±0.00 
CLz/F L/h/kg 16.50±1.49 105.70±23.63 
Cmax μg /L 16.58±1.05 0.53±0.08 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Comparison of the recovery performance of all candidate adsorbent materials by 
purifying mixed standard solutions (1.5 ng mL
-1
) with the SPE cartridges filled with one kind 
of material 
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 2 SRM chromatograms of blank plasma (a) and liver (d), blank plasma (b) and liver (e) 
spiked with AFB1 and T-2 (50 ng mL
-1
), respectively, and rat plasma (c) and liver samples (f) 
at 0.5 h after oral administration of AFB1 and T-2 in rat 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 3 Mean plasma concentration–time curves of AFB1 (a) and T-2 (b) following the oral 
administration of co-occurring AFB1 and T-2 (0.5 mg/kg b.w.) in rat (n=6) 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig. 4 The concentration–time profile of AFB1 (a) and T-2 (b) after oral administration of 
AFB1 and T-2 (0.5 mg/kg b.w.) in different tissues of rat (n=6) 
 Fig. 5 The tissue accumulation of co-occurring AFB1 and T-2 after 20 days of AFB1 and T-2 
(0.25 mg/kg b.w.) administration by oral gavage in rat (n=6) 
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Fig. S-1. Chemical structures of AFB1 (a) and T-2 (b) and the MS/MS spectrometry of AFB1 
(c) and T-2 (d). 
 
 
Table S-1 Factors, levels and the results of the orthogonal experiment L9 (3
4
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Fig. S-1. Chemical structures of AFB1 (a) and T-2 (b) and the MS/MS spectrometry of AFB1 
(c) and T-2 (d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S-1 Factors, levels and the results of the orthogonal experiment L9 (3
4
). 
  
Levels 
Factors 
1 
Ratio 
(silica gel/ florisil) 
2 
Quantity of total 
materials 
3 
Quantity of elution solvent 
(mL) 
4 
Blank 
 
(mg) 
1 9/1 0.1 1  
2 7/3 0.3 2  
3 5/5 0.5 3  
 
 
Run 1 2 3 4 
Total contents 
(ng mL
-1
) 
1 1 1 1  2.269 
2 1 2 2  2.077 
3 1 3 3  2.466 
4 2 1 2  2.262 
5 2 2 3  2.066 
6 2 3 1  1.267 
7 3 1 3  2.518 
8 3 2 1  1.318 
9 3 3 2  1.822 

X
1  
(ng mL
-1
) 
2.271 2.350 1.618 2.052  

X
2 
(ng mL
-1
) 
1.865 1.820 2.054 1.954  

X
3 
(ng mL
-1
) 
1.886 1.852 2.350 2.015  
Range 0.406 0.530 0.732 0.098  
 
Factors Sum of SSE
2
 
Degree of 
freedom 
F  
Critical Value 
of F  
Significance 
Ratio 0.313 2 20.867 19.000 * 
Quantity of 
total materials 
0.529 2 35.267 19.000 * 
Quantity of 
elution 
solvent 
0.813 2 54.200 19.000 * 
Error 0.01 2    
 
 
 
 
 
